An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Alexion Pharmaceuticals, Inc.
Summary
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
* Inclusion Criteria * Type of Participant: Participants who have completed the Blinded Treatment Period (including the PC visit) of Study 301. * Sex and Contraceptive/Barrier Requirements: Male and/or female (according to their reproductive organs and functions assigned by chromosomal complement). * Informed Consent: Participant, or legally authorized representative where relevant and allowed by law, is willing and able to comply with all study requirements and to provide signed informed consent. * Exclusion Criteria * Participants who permanently discontinued study intervention in Study 301…
Interventions
- DrugALXN2220
To be administered as an IV infusion
Locations (195)
- Research SiteIrvine, California
- Research SiteLa Jolla, California
- Research SitePalo Alto, California
- Research SiteSan Francisco, California
- Research SiteAurora, Colorado
- Research SiteWashington D.C., District of Columbia